Beverley Cuddy, a 63-year-old woman from Worcestershire, has said the weight loss drug Mounjaro has helped her save money on food, even in the face of a potential price increase.
Last month, it was announced that the cost of the highest dose could rise from £122 to £330 per month.
Ms.
Cuddy, who has lost about eight stone (51kg) since starting the medication in April 2023, said, 'Once you're on this drug, your shopping habits change completely.' She explained that she no longer spends as much at the supermarket or on takeaways, as 'they're not the reward you once thought they were.' While she admitted the price hike might be frightening for a new user, she stressed the importance of looking at 'price versus value.' Before taking the drug, Ms.
Cuddy said she was 'costing the NHS a fortune' due to frequent hospitalizations and had become reliant on others because of her poor health.
She felt fortunate to have been an early user of the drug when it was more affordable, calling it 'still expensive, but not compared to surgery.' However, Dr.
Leyla Hannbeck of the Independent Pharmacies Association warned that the price hike could push more people towards illegitimate websites selling the drug.
She advised people to seek advice from their pharmacist for a legitimate substitute, as products from unauthorized websites may be 'quite dangerous.' Ms.
Cuddy's story serves as a powerful testament to the drug's life-changing potential, but also highlights a serious concern about accessibility and safety for future users.
Last month, it was announced that the cost of the highest dose could rise from £122 to £330 per month.
Ms.
Cuddy, who has lost about eight stone (51kg) since starting the medication in April 2023, said, 'Once you're on this drug, your shopping habits change completely.' She explained that she no longer spends as much at the supermarket or on takeaways, as 'they're not the reward you once thought they were.' While she admitted the price hike might be frightening for a new user, she stressed the importance of looking at 'price versus value.' Before taking the drug, Ms.
Cuddy said she was 'costing the NHS a fortune' due to frequent hospitalizations and had become reliant on others because of her poor health.
She felt fortunate to have been an early user of the drug when it was more affordable, calling it 'still expensive, but not compared to surgery.' However, Dr.
Leyla Hannbeck of the Independent Pharmacies Association warned that the price hike could push more people towards illegitimate websites selling the drug.
She advised people to seek advice from their pharmacist for a legitimate substitute, as products from unauthorized websites may be 'quite dangerous.' Ms.
Cuddy's story serves as a powerful testament to the drug's life-changing potential, but also highlights a serious concern about accessibility and safety for future users.
